Advertisement

Current trends in antithrombotic drug device development

  • J. Fareed

Abstract

Many significant developments in the diagnosis and clinical management of thrombotic disorders have occurred recently [1– 24, 26]. Basic medical sciences have contributed remarkably in both the areas of therapeutics and diagnosis of arterial and venous thrombosis. Many newer approaches for the diagnosis and treatment of thrombotic disorders have been introduced [10, 14, 16]. This has only been possible due to the understanding of the molecular mechanisms involved in the development of thrombotic processes.

Keywords

Venous Thrombosis Arterial Thrombosis Venous Insufficiency Antithrombotic Drug Antithrombotic Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fareed J. Development of heparin fractions. Some overlooked considerations. Semin Thromb Hemostas 11(2), 227–236, 1985.CrossRefGoogle Scholar
  2. 2.
    Fareed J. Heparin, its fractions, fragments and derivatives. Semin Thromb Hemostas 11(1), 1–9, 1985.CrossRefGoogle Scholar
  3. 3.
    Fareed J. New methods in hemostatic testing. In: Fareed J (Ed). Perspectives in hemostasis. New-York, Pergamon Press, pp 310–348, 1981.Google Scholar
  4. 4.
    Fareed J, Baker WH, Hayes A, Walenga JM. Molecular markers of hemostatic activation in established atherosclerosis. Semin Thromb Hemostas 12(2), 102–109, 1986.CrossRefGoogle Scholar
  5. 5.
    Fareed J, Baker WH, Walenga JM, Messmore HL. Molecular markers of pathophysiological activation of hemostasis: Current perspectives and future trends. In: Ulutin, ON and Vinazzer H (Eds). Thrombosis and hemorrhagic diseases. Istanbul, Turkey, Gozlem Matbaachk Koll. Sto., pp 83–88, 1986.Google Scholar
  6. 6.
    Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EWJr. Molecular markers of hemostatic disorders. Implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem 29(9), 1641–1658, 1983.PubMedGoogle Scholar
  7. 7.
    Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fragments. Nouv Rev Fr Hematol 26, 267–275, 1984.PubMedGoogle Scholar
  8. 8.
    Fareed J, Messmore HL, Bermes EWJr. New perspectives in coagulation testing. Clin Chem 26(10), 1380–1891, 1980.PubMedGoogle Scholar
  9. 9.
    Fareed J, Messmore HL, Walenga JM, Bermes EWJr. Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemostas 8(4), 288–301, 1983.CrossRefGoogle Scholar
  10. 10.
    Fareed J, Walenga J, Breddin K, Caen JP. Newer avenues in antithrombotic therapy. Semin Thromb Hemostas 15(1&2), 1989.Google Scholar
  11. 11.
    Fareed J, Walenga JM. Biochemical and pharmacological considerations in the development of heparin and its depolymerized derivatives. Med J Australia 144, 21–30, 1986.Google Scholar
  12. 12.
    Fareed J, Walenga JM. Current trends in hemostatic testing. Semin Thromb Hemostas 9(4), 379–391, 1983.Google Scholar
  13. 13.
    Fareed J, Walenga JM, Bick RL, Messmore HL. Low molecular weight markers of hemostatic defects: impact of automation on the quantitation of hemostatic disorders. Semin Thromb Hemostas 9(4), 354–378, 1983.Google Scholar
  14. 14.
    Hull R, Hirsh J. Long term anticoagulant therapy in patients with venous thrombosis. Arch Int Med, 143, 2061–2063, 1983.CrossRefGoogle Scholar
  15. 15.
    ISIS-2 (Second International Study of Infarct Survival). Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 13, 349–360, 1988.Google Scholar
  16. 16.
    Lagerstedt CI, Fagher B, Olsson C, Oqvist BW. Need for long-term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 515–518, 1985.Google Scholar
  17. 17.
    Markwardt F. Pharmacological approaches to thrombin regulation. Ann NY Acad Sei USA 485, 204–214, 1986.CrossRefGoogle Scholar
  18. 18.
    Markwardt F. Pharmacology of hirudin: One hundred years after the first report of the anticoagulant agent. Biomed Biochim Acta 44, 1007–1013, 1985.PubMedGoogle Scholar
  19. 19.
    Markwardt F, Fink E, Kaiser B, Klocking HP, Nowak G, Richter M, Sturzebecher J. Pharmacological survey of recombinant hirudin. Pharmazie 43, 202–207, 1988.PubMedGoogle Scholar
  20. 20.
    Messmore HL, Walenga JM, Fareed J. Molecular markers of platelet activation. Semin Thromb Hemostas 10(4), 264–269, 1984.CrossRefGoogle Scholar
  21. 21.
    Petitti DB, Strom B, Melmon K. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 81, 255–259, 1986.PubMedCrossRefGoogle Scholar
  22. 22.
    Suarez CR, Fareed J, Tomich P. Neonatal and natural hemostasis: Value of molecular markers in the assessment of hemostastic status. Semin Thromb Hemostas 10(4), 208–284, 1984. Google Scholar
  23. 23.
    Summaria L, Caprini JA, McMillan R, Sandesara J, Axelrod CA, Mueller ME, Vagher JP, Walenga J, Fareed J. Relationship between post¬surgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. Amer Surgeon 54(3), 156–160, 1988.Google Scholar
  24. 24.
    Ulutin ON, Fareed J, Kumar A, Walenga JM, Hoppensteadt D. Pharmacologic profiling of the action of defibrotide in animal models of hemostatic and thrombotic disorders. In: Ulutin ON and Vinazzer H (Eds). Thrombosis and hemorrhagic diseases. Istanbul, Turkey. Gozlem Matbaachk Koll. Sto., pp 101–110, 1986.Google Scholar
  25. 25.
    Walenga JM, Fareed J, Hoppensteadt D, Emanuele RM. Laboratory monitoring of heparin: Old vs. new methods. CRC Critical Review in Lab Sei 22(4), 386–389, 1986.Google Scholar
  26. 26.
    Walenga JM, Fareed J, Messmore HL. Newer avenues in the monitoring of antithrombotic therapy: The role of automation. Semin Thromb Hemostas 9(4), 346–354, 1983.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • J. Fareed

There are no affiliations available

Personalised recommendations